6 Review of guidance

6 Review of guidance

6.1 The recommendations provided in this guidance are directly linked to the recommendations in the NICE technology appraisal guidance on pirfenidone for treating idiopathic pulmonary fibrosis. Therefore, should any changes be made to NICE technology appraisal guidance TA282, this guidance will be considered for review. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
January 2016

  • National Institute for Health and Care Excellence (NICE)